Answers are grounded in this paper and cite their sources.
and, accordingly, represent new players in cell-based therapy of inflammatory lung disorders. In this review article, we described molecular mechanisms involved in MSC-based therapy of acute and chronic pulmonary diseases and emphasized current knowledge and future perspectives related to the therapeutic application of MSCs in patients suffering from acute respiratory distress syndrome, pneumonia, asthma, chronic obstructive pulmonary diseases, and idiopathic pulmonary fibrosis.
No takes yet. Share an insight, caveat, or question.
Harrell et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: